Nicotine induces resistance to epidermal growth factor receptor tyrosine kinase inhibitor by α1 nicotinic acetylcholine receptor-mediated activation in PC9 cells

Shuo Wang, Koichi Takayama, Kentaro Tanaka, Masafumi Takeshita, Noriaki Nakagaki, Kayo Ijichi, Heyan Li, Yoichi Nakanishi

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Introduction: Nicotine, the major component among the 4000 identified chemicals in cigarette smoke, binds to nicotinic acetylcholine receptors (nAChRs) on non-small-cell lung cancer (NSCLC) cells and regulates cellular proliferation by activating mitogen-activated protein kinases [AQ: MAPK has been expanded to mitogen-activated protein kinases. Please approve.]and PI3K/Akt pathways. In patients with smoking-related lung cancer who continue smoking, the anticancer effect of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is weaker than that in nonsmokers; however, the precise reason for this difference remains unclear. We investigated the role of α1 nAChR subunit in this phenomenon. Methods: We screened for α1 nAChR mRNA in three NSCLC cell lines and analyzed the protein in resected primary NSCLC tissues. We used Western blot and RNA interference (siRNA) methodology to confirm the results. Results: We determined that α1 nAChR plays an essential role in nicotine-induced cell signaling and nicotine-induced resistance to EGFR-TKI. In addition, we showed that silencing of α1 nAChR subunit in NSCLC may suppress the nicotine-induced resistance to EGFR-TKI. Conclusions: These results further implicate nicotine in lung carcinogenesis, and suggest that α1 nAChR may be a biomarker for EGFR-TKI treatment and also a personalizing target molecule for patients with smoking-related lung cancer.

Original languageEnglish
Pages (from-to)719-725
Number of pages7
JournalJournal of Thoracic Oncology
Volume8
Issue number6
DOIs
Publication statusPublished - Jan 1 2013

Fingerprint

Nicotinic Receptors
Nicotine
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Non-Small Cell Lung Carcinoma
Smoking
Mitogen-Activated Protein Kinases
Lung Neoplasms
RNA Interference
Phosphatidylinositol 3-Kinases
Smoke
Tobacco Products
Small Interfering RNA
Carcinogenesis
Biomarkers
Western Blotting
Cell Proliferation
Cell Line
Lung
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Nicotine induces resistance to epidermal growth factor receptor tyrosine kinase inhibitor by α1 nicotinic acetylcholine receptor-mediated activation in PC9 cells. / Wang, Shuo; Takayama, Koichi; Tanaka, Kentaro; Takeshita, Masafumi; Nakagaki, Noriaki; Ijichi, Kayo; Li, Heyan; Nakanishi, Yoichi.

In: Journal of Thoracic Oncology, Vol. 8, No. 6, 01.01.2013, p. 719-725.

Research output: Contribution to journalArticle

Wang, Shuo ; Takayama, Koichi ; Tanaka, Kentaro ; Takeshita, Masafumi ; Nakagaki, Noriaki ; Ijichi, Kayo ; Li, Heyan ; Nakanishi, Yoichi. / Nicotine induces resistance to epidermal growth factor receptor tyrosine kinase inhibitor by α1 nicotinic acetylcholine receptor-mediated activation in PC9 cells. In: Journal of Thoracic Oncology. 2013 ; Vol. 8, No. 6. pp. 719-725.
@article{e098ad61dd6543cb9fa78979b6da85cc,
title = "Nicotine induces resistance to epidermal growth factor receptor tyrosine kinase inhibitor by α1 nicotinic acetylcholine receptor-mediated activation in PC9 cells",
abstract = "Introduction: Nicotine, the major component among the 4000 identified chemicals in cigarette smoke, binds to nicotinic acetylcholine receptors (nAChRs) on non-small-cell lung cancer (NSCLC) cells and regulates cellular proliferation by activating mitogen-activated protein kinases [AQ: MAPK has been expanded to mitogen-activated protein kinases. Please approve.]and PI3K/Akt pathways. In patients with smoking-related lung cancer who continue smoking, the anticancer effect of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is weaker than that in nonsmokers; however, the precise reason for this difference remains unclear. We investigated the role of α1 nAChR subunit in this phenomenon. Methods: We screened for α1 nAChR mRNA in three NSCLC cell lines and analyzed the protein in resected primary NSCLC tissues. We used Western blot and RNA interference (siRNA) methodology to confirm the results. Results: We determined that α1 nAChR plays an essential role in nicotine-induced cell signaling and nicotine-induced resistance to EGFR-TKI. In addition, we showed that silencing of α1 nAChR subunit in NSCLC may suppress the nicotine-induced resistance to EGFR-TKI. Conclusions: These results further implicate nicotine in lung carcinogenesis, and suggest that α1 nAChR may be a biomarker for EGFR-TKI treatment and also a personalizing target molecule for patients with smoking-related lung cancer.",
author = "Shuo Wang and Koichi Takayama and Kentaro Tanaka and Masafumi Takeshita and Noriaki Nakagaki and Kayo Ijichi and Heyan Li and Yoichi Nakanishi",
year = "2013",
month = "1",
day = "1",
doi = "10.1097/JTO.0b013e31828b51d4",
language = "English",
volume = "8",
pages = "719--725",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "6",

}

TY - JOUR

T1 - Nicotine induces resistance to epidermal growth factor receptor tyrosine kinase inhibitor by α1 nicotinic acetylcholine receptor-mediated activation in PC9 cells

AU - Wang, Shuo

AU - Takayama, Koichi

AU - Tanaka, Kentaro

AU - Takeshita, Masafumi

AU - Nakagaki, Noriaki

AU - Ijichi, Kayo

AU - Li, Heyan

AU - Nakanishi, Yoichi

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Introduction: Nicotine, the major component among the 4000 identified chemicals in cigarette smoke, binds to nicotinic acetylcholine receptors (nAChRs) on non-small-cell lung cancer (NSCLC) cells and regulates cellular proliferation by activating mitogen-activated protein kinases [AQ: MAPK has been expanded to mitogen-activated protein kinases. Please approve.]and PI3K/Akt pathways. In patients with smoking-related lung cancer who continue smoking, the anticancer effect of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is weaker than that in nonsmokers; however, the precise reason for this difference remains unclear. We investigated the role of α1 nAChR subunit in this phenomenon. Methods: We screened for α1 nAChR mRNA in three NSCLC cell lines and analyzed the protein in resected primary NSCLC tissues. We used Western blot and RNA interference (siRNA) methodology to confirm the results. Results: We determined that α1 nAChR plays an essential role in nicotine-induced cell signaling and nicotine-induced resistance to EGFR-TKI. In addition, we showed that silencing of α1 nAChR subunit in NSCLC may suppress the nicotine-induced resistance to EGFR-TKI. Conclusions: These results further implicate nicotine in lung carcinogenesis, and suggest that α1 nAChR may be a biomarker for EGFR-TKI treatment and also a personalizing target molecule for patients with smoking-related lung cancer.

AB - Introduction: Nicotine, the major component among the 4000 identified chemicals in cigarette smoke, binds to nicotinic acetylcholine receptors (nAChRs) on non-small-cell lung cancer (NSCLC) cells and regulates cellular proliferation by activating mitogen-activated protein kinases [AQ: MAPK has been expanded to mitogen-activated protein kinases. Please approve.]and PI3K/Akt pathways. In patients with smoking-related lung cancer who continue smoking, the anticancer effect of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is weaker than that in nonsmokers; however, the precise reason for this difference remains unclear. We investigated the role of α1 nAChR subunit in this phenomenon. Methods: We screened for α1 nAChR mRNA in three NSCLC cell lines and analyzed the protein in resected primary NSCLC tissues. We used Western blot and RNA interference (siRNA) methodology to confirm the results. Results: We determined that α1 nAChR plays an essential role in nicotine-induced cell signaling and nicotine-induced resistance to EGFR-TKI. In addition, we showed that silencing of α1 nAChR subunit in NSCLC may suppress the nicotine-induced resistance to EGFR-TKI. Conclusions: These results further implicate nicotine in lung carcinogenesis, and suggest that α1 nAChR may be a biomarker for EGFR-TKI treatment and also a personalizing target molecule for patients with smoking-related lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=84879506069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879506069&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e31828b51d4

DO - 10.1097/JTO.0b013e31828b51d4

M3 - Article

VL - 8

SP - 719

EP - 725

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 6

ER -